J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised

Johnson & Johnson reported Q2 2026 EPS of $2.90, beating the $2.84 Zacks Consensus, and sales of $25.3B vs $25.2B. Innovative Medicines grew 7.8% to $16.38B, with oncology strong (overall oncology +17.3% to $7.41B) while biosimilar pressure weighed on Stelara (-55.2% to $740M). J&J raised 2026 guidance, lifting reported sales to $100.8–$101.4B and adjusted EPS to $11.60–$11.75, but the stock fell >2% pre-market on a MedTech miss and only a modest sales beat.

Analysis

The key market mechanism is that JNJ is proving its mix-shift is real enough to offset mature-franchise decay, which lowers near-term estimate risk and improves the quality of the 2026 revenue bridge. That matters more than the headline beat: a company can survive LOE pressure if the replacement engine is internally funded and repeatable. The downside is valuation: after a strong YTD move, the stock likely needs evidence of sustained double-digit growth visibility before the market pays up for the next leg.

Second-order winners are the companies trying to monetize JNJ's loss of exclusivity, but the pace of erosion matters. If biosimilar uptake stays slower than the market expects, AMGN and TEVA may not see the margin-rich launch ramp they are implicitly trading on, while JNJ's immunology franchise gets a longer runoff curve than feared. The real competitive signal is that JNJ's newer assets are now large enough to compete as growth pillars rather than mere offsets, which should pressure rivals in immunology, oncology, and psychiatric launches.

The main catalyst window is the next 1-3 months: conference-call color on MedTech order trends and 2026 cadence will determine whether this is a durable reacceleration or just a clean quarter. Falsifiers are simple: sub-3% MedTech growth, accelerating Stelara erosion, or any guide that implies the 2027 growth story is slipping. Over 6-18 months, the question is whether JNJ can turn a defensive compounder into a faster-growing quality name; if not, the multiple likely stays range-bound despite higher earnings.

Key Decisions for Investors

• Buy JNJ on post-earnings weakness only if the stock stabilizes over the next 2-3 sessions; target a 6-9% upside re-rating if management confirms 2026 growth is tracking above the raised guide. Stop out if MedTech growth falls back below ~3% operationally in the next print.
• Pair trade: long JNJ / short TEVA for 1-3 months. Thesis is that biosimilar economics are being overestimated while JNJ's internal replacement cycle is underappreciated; the spread should work if Stelara erosion stays orderly.
• Do not chase AMGN on the assumption that Stelara biosimilar launch share is automatic; wait for channel checks and payer data. If uptake is slower than expected, AMGN could be a relative underperformer versus the market's current launch assumptions.
• Use the event to trim overweight exposure in procedure-sensitive medtech names if JNJ's MedTech softness looks like a broader demand signal rather than a one-off miss. The falsifier is a clear re-acceleration in the next quarter's cardiovascular/surgery growth.